# Cordis Launches SELUTION SLR™ PTA Drug-Eluting Balloon (DEB) in Japan

- Link: https://www.thailand-business-news.com/pr-news/cordis-launches-selution-slr-pta-drug-eluting-balloon-deb-in-japan
- Published: 2026-04-28T08:00:00+07:00
- Author: PR Newswire

|   |

TOKYO, April 28, 2026 /PRNewswire/ — Cordis, a global leader in interventional cardiovascular
technologies, today announces the launch and availability of the SELUTION SLR™ PTA
Drug-Eluting Balloon (DEB)^(1 )for use in Japan.

SELUTION SLR™ DEB is designed to deliver sirolimus in a controlled, sustained manner
to reduce restenosis and restore vessel function. 

The SELUTION SFA Japan clinical trial results demonstrate durable clinical outcomes
in a complex patient population, including 81.5% primary patency and 93.8% of patients
remaining free from reintervention through three years.^(2 )As the first sirolimus-
eluting balloon approved in Japan for the treatment of peripheral artery disease,
SELUTION SLR™ DEB provides an additional treatment option for physicians managing
patients in real-world clinical practice. 

Dr. Yoshimitsu Soga, Co-Principal Investigator of the SELUTION SFA Japan clinical
trial and Director of Cardiology, Kokura Memorial Hospital said, "I am pleased to
see SELUTION SLR™ DEB now available for use in clinical practice in Japan. The three-
year results from the SELUTION SFA Japan clinical trial demonstrate sustained efficacy
and safety, supporting its role as an important treatment option for patients." 

Dr. Osamu Iida, Co-Principal Investigator of the SELUTION SFA Japan clinical trial
and Director of the Department of Cardiology at Osaka International Medical & Science
Center, Osaka Keisatsu Hospital said, "SELUTION SLR™ DEB is a valuable addition 
to the treatment options for peripheral vascular disease. In my early clinical experience,
I’ve observed strong post-procedural blood flow without evidence of downstream effects
below the knee. I look forward to seeing its broader adoption in real-world clinical
practice."

"At Cordis, we recognize the impact peripheral artery disease can have on patients
and their daily lives," said George Adams, MD, Chief Medical Officer, Cordis. "The
launch of SELUTION SLR™ DEB in Japan reflects our focus on expanding innovative 
treatment options that physicians may consider based on individual patient needs.
We look forward to continuing to work with the medical community in Japan to support
patient care." 

About Cordis 
From the first guidewire to the first drug-eluting stent, Cordis has
been at the heart of cardiovascular innovation for nearly 70 years. Today, Cordis
drives transformation through internal development, Cordis-X partnerships, and strategic
acquisitions—powered by a global footprint and deep operational expertise. With 
a focus on better clinical outcomes, customer-centered service, and impactful education,
Cordis will go beyond to relentlessly pursue its mission to transform cardiovascular
care. 

 1. Brand name: SELUTION SLR PTA drug-eluting balloon catheter Medical device approval
    number: 30700BZI00031000
 2. Soga, Y. et al. 3-Year Results Following Femoropopliteal Lesion Treatment With 
    a Novel Sirolimus-Eluting Balloon. _JACC: Cardio Interv_ 2025. 18(21):2629-2637.

**Media Contact:**

Kelly May
Director, Corporate CommunicationsCordis[kelly.may@cordis.com](https://www.thailand-business-news.com/pr-news/kelly.may@cordis.com)
[www.cordis.com](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4672873-1&h=2694308368&u=https%3A%2F%2Fwww.cordis.com&a=www.cordis.com)

 [⌊Cordis Launches SELUTION SLR™ PTA Drug-Eluting Balloon (DEB) in Japan⌉](https://mma.prnasia.com/media2/2965333/Cordis__Launches_SELUTION_SLR_PTA_Drug_Eluting_Balloon_DEB_in_Japan.jpg?p=medium600)

Cordis Launches SELUTION SLR™ PTA Drug-Eluting Balloon (DEB) in Japan

Logo – [https://mma.prnasia.com/media2/1676076/5936462/Cordis_2025_Logo.jpg?p=medium600](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4672873-1&h=1009508441&u=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1676076%2F5936462%2FCordis_2025_Logo.jpg&a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1676076%2F5936462%2FCordis_2025_Logo.jpg)

Photo – [https://mma.prnasia.com/media2/2965333/Cordis__Launches_SELUTION_SLR_PTA_Drug_Eluting_Balloon_DEB_in_Japan.jpg?p=medium600](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4672873-1&h=1091375413&u=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2965333%2FCordis__Launches_SELUTION_SLR_PTA_Drug_Eluting_Balloon_DEB_in_Japan.jpg&a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2965333%2FCordis__Launches_SELUTION_SLR_PTA_Drug_Eluting_Balloon_DEB_in_Japan.jpg)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Cordis Launches SELUTION SLR™ PTA Drug-Eluting Balloon (DEB) in Japan ](http://www.prnasia.com/story/archive/4943118_AE43118_0?rand=184833)